A Phase II clinical trial (NCT01792050) investigated the efficacy of combining Indoximod with the taxane chemotherapy drug Docetaxel in treating metastatic ERBB2-negative breast cancer patients. This evidence concerns the gene ERBB2 and breast carcinoma.